CIBC Bancorp USA Inc. Makes New $10.13 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN

CIBC Bancorp USA Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 18,022 shares of the biopharmaceutical company’s stock, valued at approximately $10,133,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. WBI Investments LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $414,000. Caerus Investment Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter worth about $747,000. Captrust Financial Advisors boosted its stake in Regeneron Pharmaceuticals by 34.4% during the third quarter. Captrust Financial Advisors now owns 14,417 shares of the biopharmaceutical company’s stock worth $8,106,000 after acquiring an additional 3,694 shares in the last quarter. Coldstream Capital Management Inc. grew its holdings in Regeneron Pharmaceuticals by 85.3% in the third quarter. Coldstream Capital Management Inc. now owns 2,027 shares of the biopharmaceutical company’s stock worth $1,140,000 after purchasing an additional 933 shares during the period. Finally, Danske Bank A S purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth about $31,221,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the topic of a number of analyst reports. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Bank of America upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price objective for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Cantor Fitzgerald increased their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research note on Monday, February 2nd. Finally, Scotiabank raised their price target on Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $802.27.

Insiders Place Their Bets

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 in the last three months. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $732.87 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a market capitalization of $77.48 billion, a P/E ratio of 17.63, a price-to-earnings-growth ratio of 1.98 and a beta of 0.41. The company’s 50-day moving average is $765.35 and its 200 day moving average is $699.83.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the business earned $12.07 earnings per share. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Shareholders of record on Friday, February 20th were paid a $0.94 dividend. The ex-dividend date was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.